# Synthesize Bio: Seattle AI Profile — Product, Footprint & Verified Record

- **Canonical Web Article:** https://tygartmedia.com/synthesize-bio-seattle-wa-ai-profile/
- **Profile Brief (PDF):** https://tygartmedia.com/wp-content/uploads/2026/11/synthesize-bio-seattle-wa-ai-profile.pdf
- **Markdown Twin:** https://tygartmedia.com/wp-content/uploads/2026/11/synthesize-bio-seattle-wa-ai-profile.md
- **Snapshot Infographic:** https://tygartmedia.com/wp-content/uploads/2026/11/synthesize-bio-seattle-wa-ai-profile-infographic.png
- **Verified Date:** 2026-11-19

> **Sourced Baseline:** As of November 19, 2026, Synthesize Bio operates as an independent, Seed-stage Seattle computational biology startup at synthesize.bio. Spun out of Fred Hutchinson Cancer Center in 2023 by co-founders Jeff Leek, PhD, and Robert Bradley, PhD, the company raised a $10M Seed round led by Madrona Venture Group in September 2025 and builds generative genomics foundation models (GEM-1) and the VERDICT platform to simulate human biology and forecast clinical trial outcomes for biopharma teams.

## Verified Company Record

| Field | Verified Record (As of Nov 19, 2026) |
| :--- | :--- |
| **Company** | Synthesize Bio |
| **Official Website** | https://www.synthesize.bio/ |
| **Washington HQ** | Seattle, WA |
| **Other WA Footprint** | Fred Hutchinson Cancer Center spinout; backed by Seattle's Madrona Venture Group and AI2 Incubator |
| **Founded** | 2023 (GeekWire, Sep 16, 2025) |
| **Founders / Leadership** | Jeff Leek, PhD (Co-Founder & CEO), Robert Bradley, PhD (Co-Founder & SAB Chair), Ariel Brumbaugh (Senior Director of Business Development) |
| **Stage** | Seed |
| **Announced Funding** | $10M Seed round (Sep 2025; led by Madrona Venture Group with AI2 Incubator, Sahsen Ventures, Inner Loop Capital, and Point Field Partners) |
| **Team Size** | 16 employees (GeekWire, Sep 16, 2025); live site highlights 11 PhD scientists plus co-founders |
| **Primary Ecosystem Ties** | Fred Hutchinson Cancer Center; Madrona Venture Group; AI2 Incubator / AI House; 2026 GeekWire Awards AI Innovation finalist |

## What Synthesize Bio Builds

Synthesize Bio develops generative genomics foundation models and clinical prediction software—positioned on its [official website](https://www.synthesize.bio/) as "Virtual Human Models for Clinical Prediction"—to simulate hypothetical biology experiments before wet-lab studies or human trials are executed. Its core **GEM** model family (introduced publicly with **GEM-1** and an accompanying September 2025 bioRxiv preprint) learns from harmonized human RNA-sequencing and single-cell data to predict gene expression responses across healthy and diseased cells and tissues ([GeekWire, Sep 16, 2025](https://www.geekwire.com/2025/fred-hutch-leaders-raise-10m-for-new-ai-startup-aiming-to-expedite-drug-discovery/)).

On top of those generative expression models, Synthesize Bio builds **VERDICT**, a platform that uses simulated human biology to evaluate drug candidates and forecast clinical trial outcomes—covering statistical significance, treatment-arm direction, effect size, and serious adverse events. As co-founder Robert Bradley told GeekWire, biopharma and academic scientists regularly face costly go-or-no-go decisions with incomplete information; Synthesize Bio's goal is to give teams computational feedback earlier in R&D rather than replacing wet-lab science.

- **GEM generative expression models:** Trained on company-stated datasets spanning 800,000 bulk RNA-seq samples, 400M single cells, 22,300 unique perturbation contexts, 50+ human tissues, and 40+ therapeutic areas ([synthesize.bio](https://www.synthesize.bio/)).
- **VERDICT clinical trial prediction:** Incorporates 12,418 labelled clinical trials to forecast endpoint success, treatment direction, effect size, and serious adverse event risk for asset evaluation and trial design.
- **Retrospective validation benchmark:** On [synthesize.bio](https://www.synthesize.bio/), Synthesize Bio reports that across 1,717 held-out later clinical trials, trials VERDICT predicted as successful achieved a 70% observed success rate compared with 52% across all evaluated trials (a 35% relative gain in meeting at least one significant primary endpoint).

## Washington Footprint and Leadership

Synthesize Bio is headquartered in **Seattle, Washington**, originating as a 2023 spinout from **Fred Hutchinson Cancer Center** ([GeekWire, Sep 16, 2025](https://www.geekwire.com/2025/fred-hutch-leaders-raise-10m-for-new-ai-startup-aiming-to-expedite-drug-discovery/)). The company maintains its canonical web presence at [https://www.synthesize.bio/](https://www.synthesize.bio/) (its [company page](https://www.synthesize.bio/company) details the founding team and scientific staff, while an alternate `.com` address returns HTTP 403). No public street address is disclosed on the live site.

Co-founder and CEO **Jeff Leek, PhD** served as Chief Data Officer and J. Orin Edson Foundation Endowed Chair at Fred Hutch, was named a TIME100 AI 2025 honoree, received the Presidents' Award for top statistician under 40, and created open-source genomics software downloaded over 1.4 million times ([synthesize.bio](https://www.synthesize.bio/)). Co-founder and Scientific Advisory Board Chair **Robert Bradley, PhD** directed Fred Hutch's Translational Data Science Integrated Research Center, held the McIlwain Family Endowed Chair, conducted research on how faulty RNA splicing drives cancer, and previously co-founded Codify Therapeutics. In October 2025, Synthesize Bio hired **Ariel Brumbaugh** from Gladstone Institutes as Senior Director of Business Development ([GeekWire Tech Moves, Oct 23, 2025](https://www.geekwire.com/2025/tech-moves-allen-institute-gets-new-exec-aws-leader-shifts-roles-nuscale-names-legal-officer/)). GeekWire reported a **16-person team** at the September 2025 launch, and the live site highlights 11 PhD scientists with backgrounds at BMS, J&J, Recursion, Novo, Pathos, Freenome, and Genentech.

## Products, Users, and Public Traction

Synthesize Bio builds for biopharmaceutical drug development teams, clinical trial designers, and biotech asset and investment evaluators seeking earlier signals on whether therapeutic candidates that pass safety checks are likely to demonstrate clinical efficacy. The company maintains a Trust Center and states a SOC 2 compliance posture on [synthesize.bio](https://www.synthesize.bio/).

Specific biopharma customer names, partnership contracts, and commercial revenue figures are **not publicly disclosed**. Public ecosystem validation includes selection as a finalist for **AI Innovation of the Year** at the [2026 GeekWire Awards](https://www.geekwire.com/2026/geekwire-awards-ai-innovation-of-the-year-finalists-transform-hr-retail-biotech-and-more/) (alongside Avante, ConverzAI, Envive AI, and Spangle AI) and presenting to national venture investors at Seattle's [AI House Demo Day](https://www.geekwire.com/2026/seattles-answer-to-yc-demo-day-25-startups-pitch-investors-from-across-the-country-at-ai-house/) on Pier 70 in September 2026.

## Funding, Stage, and Place in Washington's AI Landscape

Synthesize Bio is a Seed-stage startup that emerged from stealth in September 2025 with a **$10M Seed round** led by Seattle's **Madrona Venture Group** ([GeekWire, Sep 16, 2025](https://www.geekwire.com/2025/fred-hutch-leaders-raise-10m-for-new-ai-startup-aiming-to-expedite-drug-discovery/)), joined by **AI2 Incubator**, **Sahsen Ventures**, **Inner Loop Capital**, and **Point Field Partners**. No subsequent Series A round or acquisition has been publicly disclosed through November 2026.

Within Seattle's life-sciences AI corridor, Synthesize Bio sits directly at the bridge between the city's biomedical research institutions and its applied AI investor base. Alongside Fred Hutch, the University of Washington's Institute for Protein Design, and local biotech AI peers applying foundation models to cell biology and automated lab execution, Synthesize Bio represents a Seattle thesis centered on computational biology models trained on large-scale public and clinical genomics datasets.

## Related Washington AI Profiles & Tygart Media Context

- [Clockwork Bio — Seattle AI Profile](https://tygartmedia.com/clockwork-bio-seattle-wa-ai-profile/)
- [Potato — Seattle AI Profile](https://tygartmedia.com/potato-seattle-wa-ai-profile/)
- [Polybiomics — Seattle AI Profile](https://tygartmedia.com/polybiomics-seattle-wa-ai-profile/)
- [Why AI Compute Needs a Warranty, Not Another Watermark](https://tygartmedia.com/certified-compute-warranty-not-watermark/)

## Verified Primary Sources

- [Synthesize Bio Official Website](https://www.synthesize.bio/)
- [Synthesize Bio Company & Team](https://www.synthesize.bio/company)
- [GeekWire — Fred Hutch Leaders Raise $10M for Synthesize Bio (Sep 16, 2025)](https://www.geekwire.com/2025/fred-hutch-leaders-raise-10m-for-new-ai-startup-aiming-to-expedite-drug-discovery/)
- [GeekWire — Tech Moves: Synthesize Bio Names BD Director (Oct 23, 2025)](https://www.geekwire.com/2025/tech-moves-allen-institute-gets-new-exec-aws-leader-shifts-roles-nuscale-names-legal-officer/)
- [GeekWire — 2026 GeekWire Awards AI Innovation Finalists (Apr 9, 2026)](https://www.geekwire.com/2026/geekwire-awards-ai-innovation-of-the-year-finalists-transform-hr-retail-biotech-and-more/)
- [GeekWire — AI House Demo Day (Sep 25, 2026)](https://www.geekwire.com/2026/seattles-answer-to-yc-demo-day-25-startups-pitch-investors-from-across-the-country-at-ai-house/)

## Frequently Asked Questions

### What is Synthesize Bio's connection to Fred Hutchinson Cancer Center?

Synthesize Bio spun out of Seattle's Fred Hutchinson Cancer Center in 2023. Co-founder and CEO Jeff Leek, PhD served as Fred Hutch's Chief Data Officer and J. Orin Edson Foundation Endowed Chair, while co-founder and SAB Chair Robert Bradley, PhD directed Fred Hutch's Translational Data Science Integrated Research Center and held the McIlwain Family Endowed Chair.

### What is the difference between GEM-1 and VERDICT?

GEM-1 (part of Synthesize Bio's GEM generative expression model family) is the underlying generative genomics foundation model trained on bulk RNA-seq and single-cell datasets to predict gene expression responses. VERDICT is Synthesize Bio's clinical prediction platform built on top of that generated human biology to forecast trial outcomes, effect sizes, and serious adverse events.

### How much funding has Synthesize Bio raised and how large is the team?

Synthesize Bio announced a $10M Seed round in September 2025 led by Madrona Venture Group with participation from AI2 Incubator, Sahsen Ventures, Inner Loop Capital, and Point Field Partners. GeekWire reported a 16-person Seattle team at launch, and synthesize.bio highlights 11 PhD scientists alongside the co-founders.
